Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy

BMC Surgery

Table 3 Survival data stratified according to relapse location and treatment modality; n = 87

	DFS before 2^nd treatment		A	DFS before surgery		A	RSS after surgery
	DFS before 2^nd treatment		B	DFS before chemotherapy		B	RSS after chemotherapy
	Median (months)	95%CI		Median (months)	95%CI		Median (months)	95%CI
Pulmonary	18.15	0.30–35.99	A	22.85	14.10–31.64	A	61.71	–
Pulmonary	18.15	0.30–35.99	B	7.63	4.76–10.49	B	5.99	0.0–12.3
			p-value		0.012	p-value		0.005
Hepatic	7.83	5.76–9.89	A	7.47	0.00–15.56	A	8.39	1.52–15.26
Hepatic	7.83	5.76–9.89	B	7.83	5.75–9.90	B	4.84	1.25–8.42
			p-value		0.897	p-value		0.829
Local	10.55	7.14–13.96	A	10.75	2.30–19.22	A	51.85	24.65–79.10
Local	10.55	7.14–13.96	B	7.95	2.10–13.84	B	6.20	3.41–9.89
			p-value		0.972	p-value		0.006

Patients with isolated pulmonary metastases showed the best DFS. Surgery significantly influenced PRS in patients with isolated pulmonary metastases and local recurrence. Log rank test was used to test for statistical significance. p-value ≤ 0.05 indicates significance
CI confidence interval, DFS disease free survival, RSS relapse specific survival, 2^nd treatment relapse surgery or relapse chemotherapy

ISSN: 1471-2482